Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-07-25
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 96
- Registration Number
- NCT00123591
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Taoyuan, Taiwan
Novofine Autocover Safety Needle Versus BD Safety Glide
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2016-10-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 83
- Registration Number
- NCT00121355
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Plainsboro, New Jersey, United States
Comparison of Insulin Detemir Given Once or Twice Daily in Type 1 Diabetes
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-07-08
- Last Posted Date
- 2017-06-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 520
- Registration Number
- NCT00117780
- Locations
- 🇱🇺
Novo Nordisk Investigational Site, Luxembourg, Luxembourg
A Study of the Treatment of Type 2 Diabetes With an Insulin Infusion Pump
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-06-27
- Last Posted Date
- 2016-10-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 71
- Registration Number
- NCT00115973
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, San Antonio, Texas, United States
Vagifem Low Dose for Postmenopausal Atrophic Vaginitis Symptoms
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-04-20
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 309
- Registration Number
- NCT00108849
- Locations
- 🇨🇦
Novo Nordisk Investigational Site, Winnipeg, Canada
Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-04-19
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 23
- Registration Number
- NCT00108758
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Capa-ISTANBUL, Turkey
Trial of NovoSeven® in Haemophilia - Joint Bleeds
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-04-19
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 42
- Registration Number
- NCT00108797
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Houston, Texas, United States
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-03-23
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 389
- Registration Number
- NCT00106366
- Locations
- 🇵🇷
Novo Nordisk Investigational Site, Rio Piedras, Puerto Rico
Dose Response to Recombinant Factor VIIa When Administered for Bleed
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-03-01
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 64
- Registration Number
- NCT00104455
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Overland Park, Kansas, United States
Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-02-24
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 503
- Registration Number
- NCT00104182
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Valladolid, Spain
© Copyright 2024. All Rights Reserved by MedPath